Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

MEI Pharma Shares Rise 50% on $682.5M Partnership with Japanese Company to Treat B-cell Malignancies

Shares of MEI Pharma traded higher after the company announced that it has entered into development and global licensing agreement with Kyowa Kirin for its oral selective PI3Kd inhibitor (ME-401) used for treating B-cell malignancies. Late-stage pharmaceutic...
Streetwise Reports | April 15, 2020 |

San Diego Biopharma Features 'Strong and Balanced Pipeline'

An H.C. Wainwright & Co. report discussed what sets this company's asset apart from similar products. In a March 21 research note, H.C. Wainwright & Co. analyst Andrew Fein wrote that MEI Pharma Inc.'s (MEIP:NASDAQ) oral PK3K delta inhibitor, ME-401, differentiates it...
Streetwise Reports | March 28, 2019 |

California-Based Biopharma Signs Licensing Deal for Acquired Asset

The transaction details and the drug platform's potential are addressed in an H.C. Wainwright & Co. report. In May 21 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Ligand Pharmaceuticals Inc. (LGND:NASDAQ) signed a licensing d...
Streetwise Reports | May 27, 2019 |

Bioasis Technologies: A Very BIG Year in Review

It’s been a very busy, big and ambitious year for Bioasis Technologies Inc. ( TSX-V.BTI , OTC:BIOAF , Forum ) – a biopharmaceutical company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and...
Dave Jackson | December 17, 2020 |

The Revolutionary Co. That’s Breaking Through the Blood Brain Barrier

(Click image to play video) Delivery of therapeutics across the blood-brain barrier (BBB) and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases...
Dave Jackson | December 1, 2020 |